SANDOSTATIN LAR for Endocrine neoplasm: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 5 adverse event reports in the FDA FAERS database where SANDOSTATIN LAR was used for Endocrine neoplasm.
Most Reported Side Effects for SANDOSTATIN LAR
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 117 | 29.3% | 117 | 37 |
| Diarrhoea | 49 | 12.3% | 19 | 24 |
| Malaise | 49 | 12.3% | 19 | 30 |
| Asthenia | 45 | 11.3% | 25 | 32 |
| Malignant neoplasm progression | 45 | 11.3% | 30 | 20 |
| Nausea | 37 | 9.3% | 16 | 26 |
| Weight decreased | 37 | 9.3% | 19 | 26 |
| Fatigue | 36 | 9.0% | 19 | 22 |
| Pain | 34 | 8.5% | 10 | 22 |
| Vomiting | 31 | 7.8% | 15 | 23 |
| Dyspnoea | 29 | 7.3% | 15 | 23 |
| Blood pressure increased | 26 | 6.5% | 19 | 15 |
| Dizziness | 24 | 6.0% | 7 | 15 |
| Abdominal pain | 23 | 5.8% | 10 | 15 |
| Decreased appetite | 21 | 5.3% | 10 | 14 |
Other Indications for SANDOSTATIN LAR
Acromegaly (86)
Neuroendocrine tumour (82)
Off label use (45)
Carcinoid tumour (34)
Carcinoid syndrome (31)
Pancreatic neuroendocrine tumour (25)
Diarrhoea (6)
Meningioma (6)
Metastatic carcinoid tumour (5)
Neuroendocrine carcinoma (5)